Schrodinger exec sells 31,599 shares in plan trade

A Schrodinger senior executive exercised 31,599 options and sold all resulting shares under a pre-arranged Rule 10b5-1 trading plan.

Rhea-AI Filing Summary

Schrodinger, Inc. (SDGR) reported that executive Karen Akinsanya, President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships, exercised options for 31,599 shares of common stock at an exercise price of $4.34 per share on September 17, 2026, from a fully vested option granted on November 29, 2018. On the same day, she sold 10,000 shares at $28.00 and 21,599 shares at $30.00, in total selling the 31,599 shares acquired, pursuant to a Rule 10b5-1 trading plan adopted on November 11, 2025; a remaining option position of 11,599 shares is reported, and her equity holdings include 63,545 unvested RSUs.

Insider Trade Summary 10b5-1

Exercise and Sale: 31,599 shares ($791K approx. pre-tax spread)

Exercise and Sale 4 txns

Insider Akinsanya Karen

Role See Remarks

Sold 31,599 shs ($928K)

Approx. gross sale proceeds $928K

Approx. exercise cost $137K

Approx. pre-tax spread $791K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy) F1, F3	31,599	$0.00	$0.00
Exercise	Common Stock F1, F2	31,599	$4.34	$137K
Sale	Common Stock F1, F2	10,000	$28.00	$280K
Sale	Common Stock F1, F2	21,599	$30.00	$648K

Holdings After Transaction: Stock Option (right to buy) — 11,599 contracts (Direct); Common Stock — 69,956 shares (Direct)

Footnotes (3)

1. F1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 11, 2025.
2. F2. Includes 63,545 unvested RSUs.
3. F3. This option was granted on November 29, 2018 and is fully vested.

Key Figures

Options exercised: 31,599 shares Exercise price: $4.34 per share Shares sold at $28.00: 10,000 shares +4 more

7 metrics

Options exercised 31,599 shares Common stock acquired through option exercise on September 17, 2026

Exercise price $4.34 per share Exercise price of option granted November 29, 2018

Shares sold at $28.00 10,000 shares Common stock sale on September 17, 2026

Shares sold at $30.00 21,599 shares Common stock sale on September 17, 2026

Total shares sold 31,599 shares Aggregate of same-day common stock sales

Remaining option position 11,599 shares Options reported as held after the exercise transaction

Unvested RSUs 63,545 units Restricted stock units included in reported equity holdings

Key Terms

Rule 10b5-1 trading plan, restricted stock units, fully vested

3 terms

Rule 10b5-1 trading plan regulatory

"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 11, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

restricted stock units financial

"Includes 63,545 unvested RSUs."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

fully vested financial

"This option was granted on November 29, 2018 and is fully vested."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Schrodinger (SDGR) executive Karen Akinsanya do in this Form 4 filing?

She exercised 31,599 stock options for common shares at $4.34 per share on September 17, 2026, and then sold all 31,599 resulting shares in two transactions at $28.00 and $30.00 per share under a Rule 10b5-1 trading plan.

How many Schrodinger (SDGR) shares did Karen Akinsanya sell and at what prices?

On September 17, 2026, she sold 10,000 shares at $28.00 per share and 21,599 shares at $30.00 per share, for a total of 31,599 shares sold of Schrodinger common stock.

What options did Karen Akinsanya exercise in Schrodinger (SDGR) stock?

She exercised a fully vested stock option granted on November 29, 2018 for 31,599 shares of Schrodinger common stock at an exercise price of $4.34 per share, with the option scheduled to expire on November 29, 2028.

Were the Schrodinger (SDGR) share sales by Karen Akinsanya under a Rule 10b5-1 plan?

Yes. A footnote states that these transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by Karen Akinsanya on November 11, 2025, indicating they followed a pre-arranged trading schedule.

What Schrodinger (SDGR) equity awards does Karen Akinsanya still hold after these transactions?

The filing reports a remaining option position of 11,599 shares and states that her holdings include 63,545 unvested restricted stock units (RSUs), in addition to any vested shares not quantified in this report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/21/2026 - 05:16 PM Accepted by SEC EDGAR 09/21/2026 - 05:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Akinsanya Karen

(Last) (First) (Middle)

C/O SCHRODINGER, INC.,

1540 BROADWAY, 24TH FLOOR

(Street)

NEW YORK NEW YORK 10036

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Schrodinger, Inc. [ SDGR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/17/2026		M(1)		31,599	A	$4.34	101,555(2)	D
Common Stock	09/17/2026		S(1)		10,000	D	$28	91,555(2)	D
Common Stock	09/17/2026		S(1)		21,599	D	$30	69,956(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.34	09/17/2026		M(1)			31,599	(3)	11/29/2028	Common Stock	31,599	$0	11,599	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 11, 2025.

2. Includes 63,545 unvested RSUs.

3. This option was granted on November 29, 2018 and is fully vested.

Remarks:

President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships

	/s/ Donald Shum, as attorney-in-fact for Karen Akinsanya	09/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)